Live Breaking News & Updates on நேரம் பார்ட்டல்கள்
Stay updated with breaking news from நேரம் பார்ட்டல்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Advancing research on a common form of dementia Mayo Clinic researchers have assembled a team of international experts to investigate key proteins involved in Lewy body dementia. Lewy Body Dementia Center Without Walls Investigators from Mayo Clinic s Florida campus are leading a Lewy Body Dementia Center Without Walls research initiative funded by a National Institutes of Health (NIH) specialized center-cooperative agreement grant (U54). The overall goal of the Lewy body dementia multi-institutional Center Without Walls (CWOW) initiative is to deepen the understanding of how the Alzheimer s disease-related protein, amyloid-beta, and the Parkinson s disease-related protein, alpha-synuclein, interact to affect symptom presentation, disease progression and the underlying disease process in Lewy body dementia (LBD). ....
Infrastructure on the agenda, vaccinations for kids and more things to know this week in Hudson hudsonstarobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hudsonstarobserver.com Daily Mail and Mail on Sunday newspapers.
04 Apr 2021 α-Synuclein immunotherapy is in its infancy, with few trials posting results yet. The first two completed Phase 2s, of Biogen’s cinpanemab and Prothena and Roche’s prasinezumab, were both negative. However, while the cinpanemab study was fully negative, prasinezumab posted positive results on some secondary motor measures. At the 15th International Conference on Alzheimer’s and Parkinson’s Diseases, held virtually March 9–14, Gennaro Pagano of Roche gave researchers a first look at prespecified subgroup analyses from this study, called PASADENA. It turned out that subgroups of participants whose disease progressed fastest benefited more from prasinezumab, with more slowing of motor decline. Pagano believes this is because the signal-to-noise ratio in these subgroups was greater, allowing the small effect of prasinezumab to be discerned more readily in this slow disease. ....